Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Boron in drug design: Recent advances in the development of new therapeutic agents

Full text
Santos Fernandes, Guilherme Felipe [1, 2, 3] ; Denny, William Alexander [2] ; Dos Santos, Jean Leandro [1]
Total Authors: 3
[1] Sao Paulo State Univ, Sch Pharmaceut Sci, BR-14800903 Araraquara - Brazil
[2] Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Soc Res Ctr, Auckland - New Zealand
[3] Sao Paulo State Univ, Inst Chem, BR-14800060 Araraquara - Brazil
Total Affiliations: 3
Document type: Review article
Source: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY; v. 179, p. 791-804, OCT 1 2019.
Web of Science Citations: 1

Advances in the field of boron chemistry have expanded the application of this element in Medicinal Chemistry. Boron-containing compounds represent a new class for medicinal chemists to use in their drug designs. Bortezomib (Velcade (R)), a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-containing compounds. After its approval, two other boron-containing compounds have been approved, tavaborole (Kerydin (R)) for the treatment of onychomicosis and crisaborole (Eucrisa (R)) for the treatment of mild to moderate atopic dermatitis. A number of boron-containing compounds have been described and evaluated for a plethora of therapeutic applications. The present review is intended to highlight the recent advances related to boron-containing compounds and their therapeutic applications. Here, we focused only in those most biologically active compounds with proven in vitro and/or in vivo efficacy in the therapeutic area published in the last years. (C) 2019 Elsevier Masson SAS. All rights reserved. (AU)

FAPESP's process: 18/11079-0 - Synthesis and antitubercular activity of new N-oxide compounds designed to treat multiresistant-tuberculosis
Grantee:Jean Leandro dos Santos
Support Opportunities: Regular Research Grants
FAPESP's process: 16/09502-7 - Design, synthesis and antitubercular activity of new oxazolidinones useful for the treatment of multidrug-resistant tuberculosis
Grantee:Guilherme Felipe dos Santos Fernandes
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 18/17739-2 - Synthesis of New Nitroimidazooxazine Derivatives Designed as Antitubercular Agents
Grantee:Guilherme Felipe dos Santos Fernandes
Support Opportunities: Scholarships abroad - Research Internship - Doctorate